Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of neurotensin in diagnosis on castration resistant prostate cancer neuroendocrine subtype and prognosis judgment

An endocrine subtype, neurotensin technology, applied in the field of biomedicine, can solve the problems of prostate cancer patients losing treatment opportunities, disease progression, and insensitivity to endocrine therapy in prostate cancer patients

Active Publication Date: 2014-12-24
天津市泌尿外科研究所
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

NE cells secrete a large number of neuropeptides, promote the growth of surrounding cancer cells independent of androgen through paracrine effects, and enhance the ability of anti-apoptosis and invasion and metastasis, making the disease worse [Yuan TC, et al., Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells, Endocr Relat Cancer, 2007,14(3):531-547], thus making prostate cancer patients insensitive to any endocrine therapy and making prostate cancer patients lose the chance of treatment
Currently, there are no clear diagnostic markers for predicting and diagnosing the neuroendocrine subtype of castration-resistant prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of neurotensin in diagnosis on castration resistant prostate cancer neuroendocrine subtype and prognosis judgment
  • Application of neurotensin in diagnosis on castration resistant prostate cancer neuroendocrine subtype and prognosis judgment
  • Application of neurotensin in diagnosis on castration resistant prostate cancer neuroendocrine subtype and prognosis judgment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Correlation between neurotensin and castration-resistant prostate cancer neuroendocrine

[0048] In this embodiment, the level of neurotensin in serum is the fasting level of neurotensin. The fasting level means that no food was ingested 12 hours before the blood sample was taken.

[0049] 1. All the research objects were selected from 64 cases of prostate cancer patients who had undergone anti-androgenic therapy for different periods of time confirmed by pathology in Tianjin Institute of Urology, and these subjects underwent PSA monitoring and examination in Tianjin Institute of Urology during 2014.04-2014.06. No biochemical recurrence was seen in 18 cases, and androgen resistance had occurred in the remaining 46 cases (trend resistant prostate cancer, according to EAU Guideline).

[0050] 2. Research methods

[0051] 2.1 Serum concentration detection of neurotensin

[0052] 2.1.1 Steps: collect serum samples from prostate cancer patients, use the Neuroten...

Embodiment 2

[0067] Example 2 Detection of Interference Efficiency of siRNA against Neurotensin Receptor

[0068] 1. Synthetic siRNA

[0069] Find the gene sequence of neurotensin receptor 1 (Gene ID: 4923), the gene sequence of neurotensin receptor 2 (Gene ID: 23620), the gene sequence of neurotensin receptor 3 (Gene ID: 6272). Designed and chemically synthesized by Shanghai Jikai Genetics Co., Ltd., 2.0OD (5nmol)*2, as follows:

[0070] The siRNA (siRNA) sequence information for neurotensin receptor 1 is as follows:

[0071] Forward sequence: 5'-ACACUAAUGAGAAACAUGGGU-3',

[0072] Reverse sequence: 5'-CCAUGUUUCUCAUUAGUGUCU-3';

[0073] The sequence information of siRNA (siRNA2) targeting neurotensin receptor 2 is as follows:

[0074] Forward sequence: 5'-UCAUUCUUGCAUUACAUUCAG-3',

[0075] Reverse sequence: 5'-GAAUGUAAUGCAAGAAUGAAC-3';

[0076] The sequence information of siRNA (siRNA3) targeting neurotensin receptor 3 is as follows:

[0077] Forward sequence: 5'-UCAUUCUUGCAUUACAUU...

Embodiment 3

[0092] Example 3 Effect of siRNA on Prostate Cell Neuroendocrine

[0093] 1. The procedure for establishing the neuroendocrine cell model of prostate cells is the same as in Example 2.

[0094] 2. Cell transfection: the steps are the same as in Example 2.

[0095] 3. Observation of cell morphology

[0096] The cell morphology was observed under a light microscope, and the results were as follows: Figure 6 As shown, after siRNA interferes with the expression of neurotensin receptor 1 or siRNA3 interferes with the expression of neurotensin receptor 3, or interferes with the expression of neurotensin receptor 1 and neurotensin receptor 3 at the same time, with Compared with the negative control group (siNT), the prostate cancer cells lost their pyramidal shape and dendrites and restored their original morphology.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of neurotensin in diagnosis on castration resistant prostate cancer neuroendocrine subtype and prognosis judgment. The neurotensin level in serum of a subject is detected, correlation analysis is performed on the neurotensin level and clinical data of the subject, and meanwhile a basic biological experimental verification is utilized to prove that the neurotensin and the castration resistant prostate cancer neuroendocrine subtype have large correlation. By means of the application, a novel method is provided for clinic diagnosis on the castration resistant prostate cancer neuroendocrine subtype and the prognosis judgment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to the use of neurotensin, in particular to the use of neurotensin in the diagnosis and prognosis of neuroendocrine subtypes of castration-resistant prostate cancer. Background technique [0002] Neurotensin (NT), discovered in 1973, is a linear polypeptide composed of 13 amino acids with a molecular weight of 1673. The N-terminal lacks free -NH2, and the C-terminal can be hydrolyzed by carboxypeptidase (Carboxypeptidase). Leu-leu-OH, derived from the preproneurotensin precursor, is mainly secreted by open-type N cells. Neurotensin acts through neurotensin receptors, there are three types of neurotensin receptors, neurotensin receptor 1 (NTR1), neurotensin 2 (NTR2) and neurotensin 3 (NTR3), wherein NTR1 and NTR2 are G protein-coupled receptors, and NTR3 is a non-protein-coupled receptor. Studies have shown that neurotensin and its receptors are involved in the development of can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/57434G01N33/6893G01N2800/52
Inventor 牛远杰尚芝群朱识淼蒋宁田昊孙李斌李星
Owner 天津市泌尿外科研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com